M. Vià

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

P. Campbell, M. Cazzola, C. Pascutto, 2014, Leukemia.

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

A. Rosenwald, H. Einsele, N. Müller, 2020, Haematologica.

1 High-Risk Multiple Myeloma : Integrated Clinical 2 and Omics Approach Dissects the Neoplastic Clone 3 and the Tumor Microenvironment 4

H. Einsele, A. Vacca, R. Ria, 2019 .

1 Gene Expression Comparison Between the Lymph 2 Node-Positive and Negative Reveals a Peculiar 3 Immune-microenvironment Signature and a 4 Theranostic Role for WNT Targeting in Pancreatic 5 Ductal Adenocarcinoma : A Pilot Study 6

A. Azzariti, R. Iacobazzi, O. Brunetti, 2019 .

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

M. Cazzola, M. Fumagalli, V. Ferretti, 2018, Annals of Hematology.

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

A. Rosenwald, W. Klapper, H. Einsele, 2019, Blood.

OAB-041: Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease

A. Rosenwald, H. Einsele, N. Bolli, 2021, Clinical Lymphoma Myeloma and Leukemia.